ACD-101 is under clinical development by Therapeia and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ACD-101’s likelihood of approval (LoA) and phase transition for Recurrent Glioblastoma Multiforme (GBM) took place on 21 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ACD-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ACD-101 overview

ACD-101 (131I-ACD-101) is under development for the treatment of glioblastoma multiforme, recurrent glioblastoma multiforme. The drug is administered intravenously. ACD-101 is a phenylalanine derivative that contains an iodine atom. It is a synthetic amino acid. ACD-101 is a radiation sensitizer which increases tumor killing in connection with standard external field radiation therapy (XRT), or intracellular endo-radiation therapy (ERT), using 131I-ACD-101. It acts by targeting DNA and LAT-1 (L-type amino acid transporter).

Therapeia overview

Therapeia is a developer of diagnostic and therapeutic radiopharmaceuticals for unmet medical needs. The company offers products such as ACD-101, 131I-ACD-101 and 124I-ACD-101. It offers ACD-101 which is administered intravenously over the intact blood brain barrier into tumour tissue and has an anti cancer effect. Therapeia is radio actively labeled with 131I and is used for therapy (131I-ACD-101). The company provides ACD-101 which is also used as a PET tracer for diagnosis (124I-ACD-101), when radiolabelled with 124I. Its products find it’s application in the therapeutic areas of glioma or brain cancer. Therapeia is headquartered in Dresden, Germany.

Quick View ACD-101 LOA Data

Report Segments
  • Innovator
Drug Name
  • ACD-101
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.